Navigation Links
New approach to BSE successful in lab

A new method of treatment can appreciably slow down the progress of the fatal brain disease scrapie in mice. This has been established by researchers from the Universities of Munich and Bonn together with their colleagues at the Max Planck Institute in Martinsried. To do this they used an effect discovered by the US researchers Craig Mello and Andrew Fire, for which they were awarded this year’s Nobel Prize for Medicine. Scrapie is a variant of the cattle disease BSE and the human equivalent Creutzfeld-Jakob disease. However, it will take years for the method to be introduced to medicine, the researchers warn. Their findings are published in the next issue of the Journal of Clinical Investigation (Vol. 116, No. 12, December 2006).

Scrapie, Creutzfeld-Jakob and BSE are among the most unusual diseases known to medical research. Unusual because the pathogens are apparently neither viruses nor bacteria, being simply protein molecules known as protein prions. What is even more peculiar: exactly the same prion proteins occur in healthy animals. The only difference is that they have a different shape. When there is contact with their ‘diseased twins?they change their shape, also becoming ‘diseased.?The result is an irresistible chain reaction. The malformed prion proteins can be deposited in the brain, thereby destroying brain tissue. Prion diseases are always fatal, often, however, not until months after the outbreak of the disease. As yet there is no cure.

In mice suffering from scrapie the pathogenic prion protein is known as PrP-Scr, whereas the normal variant is PrP-C. PrP-C seems to have a protective effect in diseases like a stroke. Interestingly, mice which cannot produce any PrP-C appear to be completely healthy. This has become the starting point for a new therapeutic approach which for some years now has been current in research circles: can we not simply switch off the production of ‘healthy?PrP-C in infected animals, thereby depriving the ‘di
'"/>

Source:University of Bonn


Page: 1 2 3

Related biology news :

1. Weizmann Institute scientists develop a new approach for directing treatment to metastasized prostate cancer in the bones.
2. MSI releases moleculizer - a new approach to simulation of intracellular biochemical networks
3. Stopping smallpox in its tracks: A new anti-viral approach
4. Building a protein name dictionary from full text: a machine learning term extraction approach
5. Rensselaer researchers develop approach that predicts protein separation behavior
6. Huntingtons cure in flies lays groundwork for broader treatment approaches
7. Results of worlds first gene therapy trial for arthritis show approach safe, feasible
8. Vaginal gel may provide a new approach to HIV prevention
9. Clinical trial to test stem cell approach for children with brain injury
10. Study in Science holds promise for a new approach to drug therapy
11. U-M researchers take new approach to defeating Gram-negative bugs

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New approach BSE successful lab

(Date:11/23/2009)...cal Sciences (NIGMS), part of the National Institu...r grants in scientific areas it identified as "Gra... program to stimulate biomedical research and the ...ery and Reinvestment Act (Recovery Act). , "The ...nificant impact on a field of biomedical science o...
(Date:11/23/2009)...stitute for Child Health Research has found eviden...on in pregnancy affects child behaviour in differe...ine in the international journal Addiction . , ...drawn from a random sample of more than 2000 mothe...r the baby,s delivery, and were then followed up w...
(Date:11/23/2009)... of the Interuniversity Professorship in Law and t...ersity of the Basque Country. The Professorship is...erts such as researchers in the fields of molecula.... , The Interuniversity Professorship in Law and...nd the Basque Country was created in 1993. The wor...
Breaking Biology News(10 mins):NIGMS invests in scientific Grand Opportunities with Recovery Act funds 2NIGMS invests in scientific Grand Opportunities with Recovery Act funds 3New study links alcohol in pregnancy to child behavior problems 2Research and legislation should go hand in hand, as much as possible 2Millar Instruments and Transonic Systems Suppliers of Gold Standard Pressure and Flow Products Enter Into Mutual Distribution Agreement 6256 1Millar Instruments and Transonic Systems Suppliers of Gold Standard Pressure and Flow Products Enter Into Mutual Distribution Agreement 6256 2Voler Systems President Speaks at BIOMEDevice San Jose 6253 1Voler Systems President Speaks at BIOMEDevice San Jose 6253 2Voler Systems President Speaks at BIOMEDevice San Jose 6253 3Dynatronics Announces Positive Financial Results for Quarter 6250 1Dynatronics Announces Positive Financial Results for Quarter 6250 2Dynatronics Announces Positive Financial Results for Quarter 6250 3Dynatronics Announces Positive Financial Results for Quarter 6250 4
...esearch suggests that stress may activate immune c...disease. The related report by Joachim et al., "S...in Skews Dendritic Cells towards Maturation and Mi...ppears in the November issue of The American Jour...l of defense to infection, serving not only as a p...
...t to guide their nest-mates to good food sources, ...y of London. , For any animal, finding food on it...l animals such as bees reduce these problems by in...iting, them to the search. , Honeybees use their ...irection of a food source. But bumblebees can,t co...
...bies in Germany are born with alcohol-related defe...k alcohol regularly during the pregnancy. The cons...t into adulthood. The various forms of fetal alcoh...icians Hans-Ludwig Spohr and Hans-Christoph Steinh...International ( Dtsch Arztebl Int 2008; 105[41]:...
Other Biology News:Stress may make you itch 2
(Date:11/19/2009)... , MALVERN, Pa. and WALTHAM, Mass., Nov. 19 /PR... Decision Resources find that the leading driver o...Europe is broad-spectrum activity against gram-pos...ety of organisms that can cause nosocomial pneumon...look primarily for agents that provide appropriate...
(Date:11/19/2009)..., MONTREAL, Nov. 19 /PRNewswire/ - Aegera Therapeu...patient in a randomized Phase 2B study of AEG35156...velopment for multiple oncology indications. ,,...se 2 Study of the X-Linked Inhibitor of Apoptosis ...h High-dose Cytarabine and Idarubicin in AML Follo...
(Date:11/19/2009)... World,s Top Gene Synthesis Compan...IGSC) to Coordinate Best Practices in Risk Reducti...f Worldwide Gene Synthesis Capacity , ...the world’s leading gene synthesis companies...common screening protocol to promote biosecurity i...
(Date:11/19/2009)... , VIENNA, Austria, November 19 /PRNewswire... program on one product candidate at an unexpected...te AD02 is planned to enter into,Phase II clinical...,immediately follows the completion of two Phase I...pany based its fast decision on the first interim,...
Breaking Biology Technology:Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 3World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 4AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 2AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 3
...will,grace the faculty of the "Pharma & Biotech Co...ence in two weeks in New Jersey. The conference is... Analysis, and Market,Forecasting executives; 200 ...-2 to attend the meeting. Competition has never be...or competitor moves in crowded,therapeutic classes...
... Measure Cardiac Output During Cardiop...ember 19 Cheetah Medical Inc.,developers of the C...me,cardiac output monitoring, announced at HFSA th...fficiency in heart failure are related to peak,exe...rd University and the VA Palo,Alto Health Care Sys...
...Ventures, Kleiner Perkins Caufie...of Technology Pioneer at Forefront of Developing N...EMERYVILLE, Calif., Sept. 19 Amyris Biotechnologi...ydrocarbon biofuels, today,announced that it close...nding. Duff Ackerman & Goodrich Ventures (DAG Vent...
Other Biology Technology:New Competitive Intelligence Speakers Spark Interest in Pharmaceutical Conference on October 1-2 in NJ 2Cheetah Medical's NICOM Non-Invasive Cardiac Output Monitor Featured in a Presentation at the Heart Failure Society of America (HFSA) Annual Meeting 2Cheetah Medical's NICOM Non-Invasive Cardiac Output Monitor Featured in a Presentation at the Heart Failure Society of America (HFSA) Annual Meeting 3Amyris Biotechnologies Announces $70 Million Series B Round 2
Rabbit Anti-Human MMP-13 Collagenase-3, amino terminal end of active enzyme, Antibody, Unconjugated from CEDARLANE Laboratories Limited
Mouse Anti-BCAR1 Monoclonal Antibody, Unconjugated, Clone SPM302 from Abcam
Anti-Phosphotyrosine IgG Monoclonal Antibody, Alkaline Phosphatase Conjugated, Clone AD548 from Assay Designs/Stressgen Bioreagents
Rabbit Anti-Myosin VIIa Polyclonal Antibody, Unconjugated from Abcam
Biology Products: